Navigation Links
Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
Date:9/19/2007

io of promising anticancer drugs. Lorus has completed one Phase II and one Phase III clinical trial. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward looking statements

This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: financings and corporate reorganizations, the establishment of corporate alliances, the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "expect", "intend", "will", "should", "would", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance, achievements or the transactions described in this press release to be materially different from any future results, performance, achievements transactions described in this press release, if at all, that may be expressed or implied by such forward-looking statements, including, among others: the progress of negotiations; our ability to obtain regulatory, securityholder and other approvals; our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. VBI Provides Potential Targets to Diabetes Therapeutics
2. CELL THERAPEUTICS PAYS Heavily to Resolve Dispute FOR ALLEGED ILLEGAL MARKETING OF CANCER DRUG
3. PM announces a new health care order for India
4. Ramdoss Announces Introduction of RCH-II
5. Britain Announces Third Transfusion Related Mad Cow Case
6. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
7. Tibet Announces the Dalai Lama’s Tour of South Americ
8. NHS announces further Cost cutting Measures
9. Indian PM Announces Of Setting Up India Study Center At Tashkent
10. PowderMed Announces Needle-Less Flu Vaccine
11. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Pharmacy Technician Employment Increasing Up to 32% By 2016 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4ARKRAY, Inc. Announces Partnership With scil animal care company for the SPOTCHEM(TM) EZ Analyzer 2Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 1Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 2Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 3Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 4Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 5Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 6Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study 5663 1Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study 5663 2NASCAR Camping World Truck Series Driver Aric Almirola Waves the Yellow Flag at Warning Signs of Skin Cancer 5659 1NASCAR Camping World Truck Series Driver Aric Almirola Waves the Yellow Flag at Warning Signs of Skin Cancer 5659 2NASCAR Camping World Truck Series Driver Aric Almirola Waves the Yellow Flag at Warning Signs of Skin Cancer 5659 3
Other Medicine Technology:CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 2CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 3CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 4CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8